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Cost-Effectiveness Analysis for Surgical, Angioplasty, or
Medical Therapeutics for Coronary Artery Disease
5-Year Follow-Up of Medicine, Angioplasty, or Surgery Study (MASS) II Trial
Ricardo D’Oliveira Vieira, MD; Whady Hueb, MD, PhD; Mark Hlatky, MD, PhD;
Desiderio Favarato, MD, PhD; Paulo Cury Rezende, MD; Cibele Larrosa Garzillo, MD, PhD;
Eduardo Gomes Lima, MD; Paulo Roge´rio Soares, MD, PhD;
Alexandre Ciappina Hueb, MD, PhD; Alexandre Costa Pereira, MD, PhD;
Jose´ Antonio Franchini Ramires, MD, PhD; Roberto Kalil Filho, MD, PhD
Background—The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel
coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery
(CABG, n203), percutaneous coronary intervention (PCI, n205), or medical treatment alone (MT, n203). This
investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.
Methods and Results—We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness,
adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for
event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07
quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and
2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19 967.00 for PCI; and $18 263.00 for
CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus
PCI (P0.01) and versus CABG (P0.01) and CABG versus PCI (P0.01). The event-free plus angina-free costs were
$16 553.00, $25 831.00, and $24 614.00, respectively. The paired comparison of the event-free plus angina-free costs
showed that there was a significant difference favoring MT versus PCI (P0.04), and versus CABG (P0.001); there
was no difference between CABG and PCI (P0.05).
Conclusions—In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost
effective than CABG, and CABG was more cost-effective than PCI.
Clinical Trial Registration Information—www.controlled-trials.com. Registration number: ISRCTN66068876.
(Circulation. 2012;126[suppl 1]:S145–S150.)
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Therapeutic strategies for multivessel coronary arterydisease (CAD) with stable angina and preserved ventric-
ular function are medical treatment (MT), percutaneous
coronary intervention (PCI), and coronary artery bypass graft
(CABG). All 3 treatment regimens have similar efficacy
regarding prevention of myocardial infarction (MI) and
death.1–4 The difference is that surgical patients have a lower
necessity of further revascularization procedures. In this
scenario of therapeutic equivalence, the economic conse-
quences of therapeutic strategies are an important outcome.
An initial cost of PCI is usually lower than that of CABG;
however, additional procedures, even with the use of stents,
increase the cost.5–8 Medical treatment is less costly, although
it is usually less effective for alleviating symptoms.9 This
apparent economic advantage can hide the costs applied to
the long-term follow-up with repeated examinations, minor
clinical interventions, clinical events involving hospitaliza-
tion, or even percutaneous interventions or a surgical emer-
gency. Thus, the costs of conservative treatment may hide
higher costs that interventional treatments do not hide.
Currently, there is a lack of clinical trials comparing
economic outcomes of these 3 therapeutic strategies for
multivessel CAD. Trials analyze mainly the comparative
costs between the surgical and percutaneous intervention or
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between PCI and MT.3,6–8 In fact, the prospective, random-
ized study we designed compared the hospital costs of CABG
with and without cardiopulmonary bypass under certain
conditions indicating advantages for one or another tech-
nique.10 In addition, initial data on comparative costs of
short-term follow-up surgical, percutaneous, or clinical treat-
ment revealed an initial advantage for the clinical treatment.11
This report is a post hoc analysis of a 5-year follow-up of
the second Medicine, Angioplasty, or Surgery Study (MASS
II) trial. This current investigation compares the economic
outcome of the 3 therapeutic strategies for multivessel CAD
and preserved ventricular function.
Methods
Subjects
Details of the MASS II design, study protocol, patient selection,
inclusion criteria, and general results have been previously pub-
lished.2,12 Briefly, the MASS II study was a prospective, random-
ized, controlled clinical trial designed to compare medical treatment,
angioplasty/stent placement (PCI), and surgical myocardial revascu-
larization (CABG) with cardiopulmonary bypass in patients with
stable multivessel CAD and preserved left ventricular function. The
predefined primary end point was the combined incidence of overall
mortality, MI, or persistent angina requiring revascularization. All
data were analyzed according to the intention-to-treat principle. In
other words, all randomized patients were included in all analysis,
including patients not receiving the treatment to which they were
randomized. Patients with angiographically documented proximal
multivessel coronary stenosis (70% stenosis) by visual assessment
and documented ischemia were considered for inclusion. Patients
were enrolled and randomized if the surgeons, attending physicians,
and interventional cardiologists agreed that revascularization could
be attained by either strategy. Clinical exclusion criteria included
unstable angina or acute MI requiring emergency revascularization,
ventricular aneurysm requiring surgical repair, left ventricular ejec-
tion fraction of 40%, a history of PCI or CABG, single-vessel
disease, and left main coronary artery stenosis 50%. Patients were
also excluded if they had another coexisting condition that was a
contraindication to CABG or PCI. In this trial, all patients were
placed on an optimal medical treatment for CAD.
Patients were randomized to continue with optimal MT alone or to
undergo PCI or CABG concurrently with optimal MT. All patients
received optimal medical treatment; angiotensin-converting enzyme
inhibitors, statins, -blockers, calcium channel blockers, diuretics,
and nitrates were available for all groups.
Patients were enrolled in a single clinical site at the Heart Institute
(InCor) of the University of Sa˜o Paulo Medical School in Brazil.
Patients gave written, informed consent and were randomly assigned
to a treatment group. The Ethics Committee of the Heart Institute
approved the trial, and all procedures were performed in accordance
with the Helsinki Declaration.
Clinical Follow-Up
Factors and adverse clinical events were recorded from the date the
patient signed the consent form. The patients had outpatient follow-up
quarterly in the first year and every 6 months for 5 years of follow-up.
Additional outpatient visits were available if necessary. Routine labo-
ratory tests were carried out every 6 months, and the resting electrocar-
diogram, stress test, and scintigraphic or angiographic studies were
available if angina symptoms were difficult to control.
Angina symptoms were graded according to severity, from 1 to 4,
as previously defined.13 Angina is considered unstable only when the
patients received a full dose of anti-ischemic drugs without an
effective response. The performance of a subsequent revasculariza-
tion procedure (PCI or CABG) was determined by the presence of
high-grade angina or MI. MI was considered present in accordance
with new Q waves in at least 2 electrocardiographic leads or
symptoms of chest pain characteristics associated with increased
serum levels of creatine kinase-MB 3 times above the normal
reference value. Stroke was diagnosed before the observation of the
onset of neurological deficit associated with structurally compatible
lesions identified by CT scan or MRI.
Economic Analysis
The economic analysis compared the cumulative costs of each
therapeutic strategy in the 5-year follow-up period. The resources
analyzed included: (1) for patients in the surgical or PCI group, the
costs were applied for each patient based on the standard cost of
these interventions. With the occurrence of a new intervention, the
cost was added according to the standard cost of the particular
intervention. For patients in the clinical group, charges were made
for each kind of mechanical intervention observed during follow-up;
(2) in-hospital complications of revascularization procedures; (3)
outpatients visits; (4) medications; (5) cardiovascular tests (treadmill
exercise test, echocardiogram, single photon emission CT, coronary
arteriography); (6) subsequent hospitalization for cardiovascular
disease (MI, unstable angina, stroke, and death); and (7) subsequent
revascularization procedures and in-hospital complication.
Table 1. Characteristics of the 611 Patients Assigned to MT,
PCI, and CABG in MASS II
Characteristics MT (n203) PCI (n205) CABG (n203)
Age, y 609 609 609
Female, % 31 33 28
Hypertension, % 55 61 63
Diabetes mellitus, % 36 23 29
Current or past smoker, % 33 27 32
MI, % 39 52 41
Angina CCS Class II or III, % 78 78 86
Total cholesterol, mmol/L 5.741.01 5.691.06 5.531.09
LDL cholesterol, mmol/L 3.830.88 3.800.93 3.700.93
HDL cholesterol, mmol/L 0.960.26 0.980.26 0.960.26
Triglycerides, mmol/L 2.010.93 2.040.82 1.910.95
Positive treadmill test, % 47 33 56
Mean ejection fraction, % 687 678 679
Double-vessel disease, % 41 42 42
Triple-vessel disease, % 59 58 58
LAD disease, % 89 93 93
Unless otherwise indicated, data are meanSD. Some patients had both
angina and a positive treadmill test or abnormal resting electrocardiogram.
MASS indicates Medicine, Angioplasty, or Surgery Study; MT, medical
treatment; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; MI, myocardial infarction; CCS, Canadian Cardiovascular Society;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; LAD, left anterior
descending.
Table 2. Major Adverse Cardiac Events at 5-Y Follow-Up
End Point
MT
(n203)
PCI
(n205)
CABG
(n203)
P Value
(2)
AMI (%) 44 (21.7) 44 (21.5) 27 (13.3) 0.082
Additional
revascularization (%)
68 (33.5) 85 (41.5) 9 (4.4) 0.0001
PCI (%) 28 (13.8) 64 (31.2) 7 (3.4) 0.0001
CABG (%) 40 (19.7) 21 (10.2) 2 (0.01) 0.0001
Stroke (%) 15 (7.4) 12 (5.9) 20 (9.9) 0.31
MT indicates medical treatment; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; AMI, acute myocardial infarction.
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Costs are expressed in US dollars. Costs of resources in our
institution are: $10 294.00 for CABG; $2647.00 for angioplasty
(PCI); $2282.00 for each bare metal stent; $5882.00 for hospitaliza-
tion due to MI; $5294.00 for hospitalization due to unstable angina;
$3529.00 for hospitalization due to stroke; $705.00 for a coronary
angiogram; $362.00 for single photon emission CT; $85.00 for an
echocardiogram; $47.00 for a treadmill exercise test; and $24.00 for
outpatient visits. The estimated mean costs of in-hospital complica-
tions of a revascularization procedure are: $6470.00 for cardiogenic
shock and use of intra-aortic counterpulsation balloon; $5882.00 for
nosocomial pneumonia or acute respiratory distress syndrome;
$2941.00 for acute renal failure and hemodialysis; $7058.00 for
mediastinitis or sternum osteomyelitis; and $5000.00 for cardiac
surgery because of bleeding and/or cardiac tamponade.
The 5-year medication costs were based on Arterial Revascular-
ization Therapies Study (ARTS) trial. It was $5000.00 for PCI and
CABG treatments and $6000.00 for MT group.8,14
Cost-Effectiveness
Cost-effectiveness analysis was performed by quality-adjusted life-
year (QALY). It was combined evidence of effectiveness and the
cost of the treatment expressed in dollars per event-free year of life
gained from each treatment modality. An additional adjustment was
made for the angina-free proportion at 5-year evaluation.
Thus, an adjustment for 5 years’ event-free costs was made
multiplying the actual costs by the ratio 5 over average time to the
first event; further adjustment was made for angina alleviation by
the ratio of event-free costs over angina free proportion. Thus, we
introduced a QALY analysis in the present study for event-free
survival and event and angina-free survival.
Statistical Analysis
Statistical analysis was carried out by using the t test and analysis of
variance for normally distributed variables, nonparametric analysis
of variance for non-Gaussian distribution, and 2 for categorical
variables. The pairwise probability values were calculated using the
2-sided method. The average time to first event was used to adjust
costs and was based on Kaplan-Meier curves as previously pub-
lished.2 Values of P0.05 were considered statistically significant.
Cumulative costs were compared on the intention-to-treat basis.
Statistical analysis was performed with SAS 9.1 software (SAS
Institute Inc, Chicago, IL).
Results
A total of 611 eligible patients who had all met inclusion
criteria were randomly assigned to one of 3 therapeutic
treatments: CABG (n203), PCI (n205), or MT (n203).
Randomization created balanced treatment groups with re-
spect to important prognostic characteristics, as shown in
Table 1. All patients received medical regimens according to
a predefined approach. No patient was lost to follow-up. The
minimal duration of follow-up was 5 years. Major adverse
cardiac events at the 5-year follow-up are demonstrated in Table 2.
As reported previously, there is a significant statistical
difference in the incidence of the primary end point among
these groups.2 The patients allocated to the CABG group had
a lower incidence of the primary end point. No difference
existed in overall mortality and nonfatal MI among the
groups. The frequency of additional revascularization was the
only component of the primary end point that was signifi-
cantly different between the groups: 3.5% of patients under-
going CABG, 24% of medical patients, and 32% of stenting
patients.
Surgical Therapy
Of the 203 randomized patients, 198 underwent CABG with
an average of 10 days of hospitalization. It was recorded, as
in-hospital complications of revascularization procedures, 7
episodes of stroke, 4 episodes of cardiogenic shock with use
of an intra-aortic balloon pump, 4 of acute renal failure and
hemodialysis, one cardiac surgery for cardiac tamponade, 11
nosocomial pneumonias, and 2 episodes of wound infection.
During the 5-year follow-up, 2 patients required another
surgery, and 7 patients required PCI (mean, one stent per
patient). During the follow-up, 11 episodes of unstable
angina, 20 strokes, and 32 deaths were recorded. After
randomization, 901 treadmill exercise tests, 310 echocardio-
grams, 40 single photon emission CTs, 67 coronary arteriog-
raphies, and 2350 outpatient visits were performed. The
Figure 1. Five-year costs among 3 therapeutics strategies. The
medians of medical treatment and CABG are equal to the 25th
percentile. Tukey comparison: MTPCI and CABG (P0.0001);
PCI and CABG (P0.05). MT indicates medical treatment; PCI,
percutaneous coronary intervention; CABG, coronary artery
bypass graft.
Figure 2. The proportion of expenditure
by the cumulative cost. MT indicates
medical treatment; PCI, percutaneous
coronary intervention; CABG, coronary
artery bypass graft.
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median cumulative cost of the surgical treatment, after 5
years of follow-up, was $16 072.00 per patient.
Medical Therapy
Two hundred three patients were randomized to MT. After 5
years of follow-up, 40 patients underwent surgical revascu-
larization (mean 11.6 days of hospitalization). It was rec-
orded, as in-hospital complications of revascularization pro-
cedures, 2 episodes of stroke, 2 nosocomial pneumonias, and
one episode of mediastinitis. In addition, 28 PCIs were
performed (average of 3.7 days of hospital stay and 1.1 stent
per patient). After 5 years of follow-up, there were 8 episodes
of unstable angina, 15 strokes, and 35 deaths. After random-
ization, 920 treadmill exercise tests, 355 echocardiograms, 24
single photon emission CTs, 87 coronary arteriographies, and
2458 outpatient visits were performed. The median cumula-
tive cost of the medical group was $6876.00 per patient.
Percutaneous Coronary Intervention
Of the 205 randomized patients, 194 underwent PCI (average
of 3.46 days of hospitalization and 1.32 stents per patient). It
was recorded, as in-hospital complications of revasculariza-
tion procedure, 2 episodes of stroke, 2 episodes of emergency
CABG, and 2 additional emergency PCIs. After 5 years of
follow-up, 64 additional PCIs were necessary (average of 3.1
days of hospitalization and 0.78 stent per patient). In addition,
21 CABGs were performed (mean 12 days of hospital stay).
After the follow-up period, there were a total of 22 episodes of
unstable angina, 12 strokes, and 28 deaths. Furthermore, 988
treadmill exercise tests, 311 echocardiograms, 123 single photon
emission CTs, 138 coronary arteriographies, and 2593 outpatient
visits were performed. The median cumulative cost of the
treatment group angioplasty was $14 337.00 per patient.
The paired comparison of the cumulative costs showed that
there was a significant difference favoring MT versus PCI
(P0.01) and versus CABG (P0.01); there was no differ-
ence between CABG and PCI. The cumulative cost of each
treatment group, with the 25% and 75% percentiles, and
minimal and maximal values is demonstrated in Figure 1. The
proportion of expenditure by the cumulative cost in each
treatment group is demonstrated in Figure 2, whereas median
of costs among 3 therapeutic strategies are shown in Figure 3.
Cost-Effectiveness
To analyze the cost-effectiveness, as cited in the methodology,
the average event-free time and angina-free proportion were
calculated, as demonstrated in Table 3. The average time for first
event was 3.79 years for MT, 3.59 years for PCI, and 4.4 years
for CABG. There is a significant statistical difference favoring
surgical patients (P0.0026). At 5-year follow-up, 54.8% of the
MT group was free of angina. On the other hand, the angina-free
proportion was 77.3% for PCI and 74.2% for CABG with a
significant statistical difference in comparison with medical
group patients (P0.001). Therefore, respectively, for event-
free survival and event plus angina free survival, MT presented
3.79 QALYs and 2.07 QALYs; PCI presented 3.59 and 2.77
QALYs; and CABG demonstrated 4.4 and 2.81 QALYs.
At the 5-year follow-up, the event-free costs were
$9071.00 for MT; $19 967.00 for PCI; and $18 263.00 for
CABG. All these figures represent the median cumulative
cost for each patient during 5 years of follow-up. The paired
comparison of the event-free costs showed that there was a
significant difference favoring MT versus PCI (P0.01) and
versus CABG (P0.01); a significant difference favored
CABG versus PCI (P0.01), as shown in Figure 4.
The event-free plus angina-free costs were $16 553.00 for
MT; $25 831.00 for PCI; $24 614.00 for CABG. All these
figures represent the median cumulative cost for each patient
Table 3. Event-Free and Angina-Free Proportion
MT
(n203)
PCI
(n205)
CABG
(n203)
P
Value
Average time to
first event, y
3.79 3.59 4.4 0.0026*
Angina-free (%) 111 (54.8) 159 (77.2) 151 (74.2) 0.001†
MT indicates medical treatment; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft.
*Log-rank; CABG presented a statistically significant longer time to event.
†2 test; MT presented a statistically significant lesser proportion of
angina-free patients.
Figure 3. Composition of Costs in MASS
II, 5-year follow-up. MASS indicates Med-
icine, Angioplasty, or Surgery Study; ACS,
acute coronary syndrome; CABG, coro-
nary artery bypass graft; MT, medical
treatment; PCI, percutaneous coronary
intervention.
Figure 4. Event-free costs for each patient at 5-year follow-up.
The median was equal to the 25th percentile in MT and CABG.
Tukey multiple comparison: MT versus PCI and CABG;
P0.001; CABG versus PCI; P0.04. MT indicates medical
treatment; PCI, percutaneous coronary intervention; CABG, cor-
onary artery bypass graft.
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during 5 years of follow-up. The paired comparison of the
event-free plus angina-free costs showed that there was a
significant difference favoring MT versus PCI (P0.01) and
versus CABG (P0.01); there was no difference between
CABG and PCI, as shown in Figure 5. Refinements of
comparative costs among event-free patients and those with
crossover are shown in Table 4.
Discussion
The MASS II trial demonstrated a higher rate of repeat
revascularizations in MT and PCI groups compared with the
CABG group; the worst health-related quality of life also
occurred in the MT patients secondary to the reduced angina-
free proportion. However, regarding a hard event such as MI
or death, there was no difference among these 3 regimens.
This is a good scenario to compare cost-effectiveness, a
randomized trial demonstrating a similar hard end point. Cost
analysis is a challenging task with so many potential bi-
ases.15–18 To minimize such biases, this report performed an
extensive cost analysis, trying to account for the global cost
of the management of randomized patients with chronic
coronary disease, in a long-term follow-up: outpatient visits,
medication, cardiovascular tests, hospitalization for cardio-
vascular disease, revascularization procedures, and in-
hospital complications of revascularization procedures.
This current analysis demonstrates that MT was more
cost-effective than CABG, and CABG was more cost-
effective than PCI for event-free survival. This result is
consistent with the previous economic outcomes reported by
other randomized clinical trials.3,4,19 On the other hand, MT
was the most cost-effective approach; this advantage can be
attributed to clinical stability and also to better ventricular
function. Moreover, in this study, the angina-free status of the
population was the driver of clinical outcomes.
Some other randomized clinical trials do compare PCI with
MT. The second Randomized Intervention Treatment of Angina
(RITA-2) trial demonstrated an overall mean additional cost of
$4194.00 per patient over a 3-year period in patients randomized
to PCI.19 The Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) trial demonstrated
that the addition of PCI to optimal MT in the early management
of symptomatic patients is not a cost-effective measure. In this
trial, the cumulative cost was significantly higher ($10 125.00)
in the PCI group. The cost estimated for the improvement of
angina was $154 580.00 for one patient.3 Recently, Hlatky et al4
reinforced the strategy of MT over prompt revascularization
with PCI. Revascularization increases 4-year cost significantly,
approximately $5700.00.
In the context of the comparison of CABG to MT, there is a
lack of randomized clinical trials. The MASS II trial, in a 1-year
follow-up, demonstrated a higher cost for CABG over MT.
Furthermore, MT had the greatest increase in expected costs
(317% versus 21%), because of its lowest ratio of alleviation of
angina.11 Most recently, based on the 4-year Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) data, it
was demonstrated that medical costs were higher for surgical
revascularization than for medical therapy ($20 300.00;
P0.0001).4 It is interesting that, in our 5-year follow-up, this
economic advantage of MT remains present in a population with
more extensive anatomic disease and severe angina symptoms.
Nearly 60% of patients had triple-vessel disease with proximal
left anterior descending disease, and nearly 80% had Canadian
Cardiovascular Society Class II or III angina.
Regarding CABG versus PCI, the medical care cost was
compared in the Bypass Angioplasty Revascularization In-
vestigation (BARI) trial. After a mean 11.4-year follow-up,
there was no difference between the cumulative costs of both
strategies. The hospital cost of surgical patients was higher.
Patients in the PCI group had a greater necessity for reinter-
vention and higher cost of drug therapy (P0.009). The
randomization of this study occurred between August 1988
and August 1991; therefore, the methodological limitation is
the lack of availability of the stent, and only balloon angio-
plasty was performed. With the lack of this device, a
contemporary economic analysis becomes difficult.7 In 2001,
the cost-effectiveness of the ARTS was published.14 At the end
of the index procedure, the total cost of PCI compared with
CABG was significantly lower ($6441.00 versus $10 653.00;
P0.001), a total net difference of $4212.00. However, due to
Figure 5. Event-free and angina-free for each patient at 5-year
follow-up. Median is equal to the 25th percentile in MT and
CABG. Tukey multiple comparison: MT versus PCI and CABG;
P0.0001; PCI versus CABG; P0.05. MT indicates medical
treatment; CABG, coronary artery bypass graft; PCI, percutane-
ous coronary intervention.
Table 4. Five-Year Median Costs of the 3 Therapeutic Strategies
Treatment
No Crossover
(n513)
Crossover
(n98)
Medical no. (US $) 135 (6740.00; 6655.00–7266.25) 68 18 211.00; 17 679.00–23 712.00
PCI no. (US $) 182 14 328.00; 11 290.00–18 724.00 23 18 408.00; 9276.00–19 415.00
CABG no. (US $) 196 16 060.00; 15 949.00–19 189.50 7 16 068.00; 16 123.00–19 361.00
The data are medians; percentile 25% and 75%. Crossover was considered the occurrence of failure of initial treatment
with indication to a different nonrandomized treatment option.
PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass graft.
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the high recurrence rate of revascularization in the PCI group
compared with CABG (21% versus 3.8%), the difference de-
clined to $2973.00 in the first year of follow-up. Considering the
reduction of approximately 14% in the combined event rate
provided by CABG (73.8% versus 87.8%), and the high inci-
dence of further reintervention procedures, the time limitation of
a 1-year follow-up of this study is a methodological constraint to
achieving an economic analysis.8
Our result reinforces the fact that to minimize bias, it is
necessary to make an economic analysis in a late follow-up.
In our first year of analysis, initial average cost of treating a
patient randomized to PCI was approximately 75% of that for
the surgical therapy. Moreover, at 5-year follow-up, CABG
becomes more cost-effective for the prevention of the com-
posite primary end point and angina. A similar finding was
obtained in the BARI trial; after the initial revascularization,
the cost of PCI (without stents) was 35% lower than CABG.7
However, at the end of 5 years, this difference decreased to
5%. After 12 years, there was no difference between the
average cumulative costs of both interventional strategies
(PCI$120 750.00 versus CABG$123 000.00; P0.55).
An important observation is the low cost-effectiveness for
the improvement of angina in a population with extensive
CAD and severe angina symptoms. Compared with the
medical therapy group, PCI and CABG groups experienced
significantly better angina relief. This fact decreased 82% of the
cost-effectiveness of MT. As previously demonstrated, the cost
estimated for the improvement of angina is very high.3
Final Considerations and Conclusion
In conclusion, this current analysis demonstrates that the adop-
tion of prompt revascularization, with PCI or CABG, is more
expensive and less cost-effective than providing an initial optimal
medical treatment and performing a revascularization procedure
only when necessary. Additionally, when revascularization be-
comes necessary, surgical therapy is the most cost-effective.
To our knowledge, this is the first randomized trial that
compares, in a long-term economic outcome, these 3 thera-
peutic strategies for patients with multivessel CAD and
preserved ventricular function. We believe that this report
provides important information for public health, optimizing
healthcare spending and sparing expenses.
On the other hand, assuming that all systems of healthcare
financing can encompass a methodological bias, we think the
most accurate model to reflect the actual costs are based on
private payers. This model would be considered “real world.”
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